KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to -$553.0 million.

  • Amgen's Non Operating Income rose 2928.39% to -$553.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 billion, marking a year-over-year increase of 42391.3%. This contributed to the annual value of $2.7 billion for FY2025, which is 42391.3% up from last year.
  • According to the latest figures from Q4 2025, Amgen's Non Operating Income is -$553.0 million, which was up 2928.39% from $2.1 billion recorded in Q3 2025.
  • In the past 5 years, Amgen's Non Operating Income ranged from a high of $2.1 billion in Q3 2025 and a low of -$782.0 million during Q4 2024
  • For the 5-year period, Amgen's Non Operating Income averaged around $271.8 million, with its median value being $12.0 million (2021).
  • As far as peak fluctuations go, Amgen's Non Operating Income plummeted by 417692.31% in 2022, and later skyrocketed by 74595.74% in 2025.
  • Quarter analysis of 5 years shows Amgen's Non Operating Income stood at $162.0 million in 2021, then plummeted by 141.36% to -$67.0 million in 2022, then surged by 700.0% to $402.0 million in 2023, then crashed by 294.53% to -$782.0 million in 2024, then increased by 29.28% to -$553.0 million in 2025.
  • Its Non Operating Income stands at -$553.0 million for Q4 2025, versus $2.1 billion for Q3 2025 and -$394.0 million for Q2 2025.